单细胞RNA序列分析显示USP32是缓解PD-L1驱动的结直肠瘤发生的治疗标in vitro和in vivo

Girish Birappa1, Haribalan Perumalsamy2,3, Seok-Ho Hong4

  • 1Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.

Theranostics
|December 8, 2025
PubMed
概括

研究人员将USP32确定为一个关键的二化酶 (DUB),该酶在结肠直肠癌 (CRC) 中稳定了编程死亡连接体1 (PD-L1). 向USP32可降低PD-L1,抑制CRC细胞的增殖和瘤发生.